Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Withdrawn × tipifarnib × Clear all

Phase

Phase 2 1 Phase 1 1

Status

Completed 18 Terminated 2 Withdrawn 1 Unknown 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Interventions

Cyclophosphamide 30 Radiotherapy 21 Cisplatin 20 fludarabine 19 Paclitaxel 17 Nivolumab 16 Magnetic Resonance Spectroscopy 16 fludarabine phosphate 14 Carboplatin 14 pembrolizumab 13 Specimen Handling 13 Gemcitabine 13 Radiation 11 Biopsy 11 Docetaxel 10 Melphalan 9 Filgrastim 9 Etoposide 9 Dexamethasone 9 Cytarabine 9 Radiosurgery 8 Granulocyte Colony-Stimulating Factor 8 Doxorubicin 8 venetoclax 7 trametinib 7 durvalumab 7 Sorafenib 7 Rituximab 7 Pemetrexed 7 Ipilimumab 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05693090 2023-03-06

Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung Cancer

Kura Oncology, Inc.

Phase 1 Withdrawn

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡